RU95122819A - BICYCLIC CARBONIC ACIDS, ANTAGONISTS OF LEUKOTRIENE * 004 - Google Patents
BICYCLIC CARBONIC ACIDS, ANTAGONISTS OF LEUKOTRIENE * 004Info
- Publication number
- RU95122819A RU95122819A RU95122819/04A RU95122819A RU95122819A RU 95122819 A RU95122819 A RU 95122819A RU 95122819/04 A RU95122819/04 A RU 95122819/04A RU 95122819 A RU95122819 A RU 95122819A RU 95122819 A RU95122819 A RU 95122819A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compound
- compounds
- compound according
- paragraphs
- Prior art date
Links
- 150000002617 leukotrienes Chemical class 0.000 title claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 title 1
- 230000003042 antagnostic Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 36
- 201000010099 disease Diseases 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 206010003246 Arthritis Diseases 0.000 claims 4
- 208000006673 Asthma Diseases 0.000 claims 4
- 208000010247 Contact Dermatitis Diseases 0.000 claims 4
- 206010012442 Dermatitis contact Diseases 0.000 claims 4
- 206010056819 Gastric disease Diseases 0.000 claims 4
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 206010061598 Immunodeficiency Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 206010022114 Injury Diseases 0.000 claims 4
- 206010061255 Ischaemia Diseases 0.000 claims 4
- 208000009856 Lung Disease Diseases 0.000 claims 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 4
- 206010039083 Rhinitis Diseases 0.000 claims 4
- 208000001492 Stomach Disease Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 230000036770 blood supply Effects 0.000 claims 4
- 230000001684 chronic Effects 0.000 claims 4
- 201000003883 cystic fibrosis Diseases 0.000 claims 4
- 201000004624 dermatitis Diseases 0.000 claims 4
- 231100000406 dermatitis Toxicity 0.000 claims 4
- 231100000080 dermatitis contact Toxicity 0.000 claims 4
- 201000005569 gout Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 200000000018 inflammatory disease Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 230000000720 neurosecretory Effects 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 201000004681 psoriasis Diseases 0.000 claims 4
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- VNYSSYRCGWBHLG-AMOLWHMGSA-N Leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- WCOXUKLRXZBRTN-UHFFFAOYSA-N 2-cinnamylidenecyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1=CC=CC1=CC=CC=C1 WCOXUKLRXZBRTN-UHFFFAOYSA-N 0.000 claims 1
- AEFYTMRQBAGEHI-UHFFFAOYSA-N 3-[3-oxo-2-(3-phenylpropyl)cyclohexen-1-yl]oxypropanenitrile Chemical compound O=C1CCCC(OCCC#N)=C1CCCC1=CC=CC=C1 AEFYTMRQBAGEHI-UHFFFAOYSA-N 0.000 claims 1
- ISTGDMOCGWBUAE-UHFFFAOYSA-N 4-[2-(2-carboxyethyl)-3-[6-[[4-oxo-8-(3-phenylpropyl)-2,3-dihydrochromen-7-yl]oxy]hexyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCCCCOC=2C(=C3OCCC(=O)C3=CC=2)CCCC=2C=CC=CC=2)=C1CCC(O)=O ISTGDMOCGWBUAE-UHFFFAOYSA-N 0.000 claims 1
- IAOWURJOGYYSOV-UHFFFAOYSA-N 4-[2-(2-carboxyethyl)-3-[6-[[5-oxo-1-(3-phenylpropyl)-7,8-dihydro-6H-naphthalen-2-yl]oxy]hexyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCCCCOC=2C(=C3CCCC(=O)C3=CC=2)CCCC=2C=CC=CC=2)=C1CCC(O)=O IAOWURJOGYYSOV-UHFFFAOYSA-N 0.000 claims 1
- CLYDRRKSNPDWFS-RIYZIHGNSA-N 4-[2-(2-carboxyethyl)-3-[6-[[5-oxo-1-[(E)-3-phenylprop-2-enyl]-7,8-dihydro-6H-naphthalen-2-yl]oxy]hexyl]phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CCCCCCOC=2C(=C3CCCC(=O)C3=CC=2)C\C=C\C=2C=CC=CC=2)=C1CCC(O)=O CLYDRRKSNPDWFS-RIYZIHGNSA-N 0.000 claims 1
- 210000000278 Spinal Cord Anatomy 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- 238000007127 saponification reaction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- MIJSLEJNXATIBG-UHFFFAOYSA-N CCCCc(c(O)ccc12)c1OCCC2=O Chemical compound CCCCc(c(O)ccc12)c1OCCC2=O MIJSLEJNXATIBG-UHFFFAOYSA-N 0.000 description 2
- RNGNCCMCKXLNFP-UHFFFAOYSA-N CCCCc(c(OCC1)c(cc2)C1=O)c2OCCCCCCC1=C(CCO)C(OCCCO)=CCC1 Chemical compound CCCCc(c(OCC1)c(cc2)C1=O)c2OCCCCCCC1=C(CCO)C(OCCCO)=CCC1 RNGNCCMCKXLNFP-UHFFFAOYSA-N 0.000 description 1
Claims (20)
где R2 в каждом случае независимо друг от друга означают гидроксильную группу, низшую алкоксильную группу или NR3R4, где R3 и R4 независимо друг от друга означает водород или низший алкил и Ph означает фенил, и для соединения формулы C - его геометрический изомер, и в случае, когда R2 означает гидроксильную группу, фармацевтически применяемая соль этого соединения с основанием.1. The compound of the formula
where R 2 in each case, independently of one another, denotes a hydroxyl group, a lower alkoxy group or NR 3 R 4 , where R 3 and R 4 independently of one another denote hydrogen or lower alkyl and Ph means phenyl, and for the compound of formula C it is the geometric isomer, and in the case when R 2 is a hydroxyl group, the pharmaceutically acceptable salt of this compound with a base.
где Ph означает фенил.8. Compound 2- (3-phenylpropenylidene) -1,3-cyclohexanedione of the formula
where Ph means phenyl.
где Ph означает фенил.9. Compound 3- (2-cyanoethoxy) -2- (3-phenylpropyl) -2 cyclohexen-1-one of the formula
where Ph means phenyl.
а) для получения соединений формул А или В, где R2 означает низший алкокси или водород, взаимодействие соединения формулы
с соединением формулы
R2′
где R2' обозначает низший алкокси или водород и L обозначает отщепляющуюся группу,
или
б) для получения соединений фформулы А, где R2 имеет указанные выше значения, каталитическое гидрирование соединения формулы
где R2 имеет указанные выше значения,
или
(в) для получения соединений формулы В, где R2 имеет указанные выше значения, каталитическое гидрирование соединения формулы С, где R2 имеет указанные выше значения, или
(г) для получения соединений формулы C, где R2 имеет указанные выше значения, взаимодействие соединения формулы
где R2 имеет указанные выше значения,
с соединением
PhL II-4
где Ph означает фенил и L обозначает отщепляющуюся группу, или
д) для получения соединений формул А, В и С, где R2 обозначает гидроксильную группу, омыление соединения А, В или С, где R2 означает низший алкокси, и
е) для получения соединений формул А, В и С, где R2 означает -NR3R4 и R3 и R4 имеют указанные выше значения, превращение соединения формулы А, В или С, где R2 означает гидроксильную группу, в соответствующее соединение, где R2 означает -NR3R4,
ж) если желательно, превращение соединения формул А, В и С в его фармацевтически применимую соль.12. The method of obtaining compounds according to any one of paragraphs.1 to 7, which includes
a) to obtain compounds of formulas a or b, where R 2 means lower alkoxy or hydrogen, the interaction of the compounds of formula
with compound of formula
R 2 ′
where R 2 ′ is lower alkoxy or hydrogen and L is a leaving group,
or
b) to obtain compounds of the formula A, where R 2 is as defined above, catalytic hydrogenation of a compound of the formula
where R 2 has the above values,
or
(c) for the preparation of compounds of the formula B, where R 2 is as defined above, catalytic hydrogenation of a compound of formula C, where R 2 is as defined above, or
(g) to obtain compounds of the formula C, where R 2 has the above values, the interaction of the compounds of the formula
where R 2 has the above values,
with compound
PhL II-4
where Ph means phenyl and L denotes a leaving group, or
d) to obtain compounds of formulas a, b and C, where R 2 denotes a hydroxyl group, the saponification of compounds a, b or C, where R 2 means lower alkoxy, and
e) to obtain compounds of formulas A, B and C, where R 2 is —NR 3 R 4 and R 3 and R 4 are as defined above, the conversion of a compound of formula A, B or C, where R 2 is a hydroxyl group, to the corresponding a compound wherein R 2 is —NR 3 R 4 ,
g) if desired, the conversion of the compound of formulas A, B and C into its pharmaceutically applicable salt.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/164,116 US5457124A (en) | 1993-12-07 | 1993-12-07 | Carboxylic acid Leukotriene B4 antagonists |
US164116 | 1993-12-07 | ||
US164.116 | 1993-12-07 | ||
PCT/EP1994/003918 WO1995015956A1 (en) | 1993-12-07 | 1994-11-26 | Bicyclic carboxylic acid leukotriene b4 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95122819A true RU95122819A (en) | 1997-09-27 |
RU2137765C1 RU2137765C1 (en) | 1999-09-20 |
Family
ID=22593046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95122819A RU2137765C1 (en) | 1993-12-07 | 1994-11-26 | Bicyclic carboxylic acids inhibiting biological activity of leukotriene b4 and pharmaceutical composition |
Country Status (14)
Country | Link |
---|---|
US (1) | US5457124A (en) |
EP (1) | EP0682662B1 (en) |
JP (1) | JPH08508515A (en) |
CN (1) | CN1117290A (en) |
AT (1) | ATE183506T1 (en) |
AU (1) | AU682737B2 (en) |
BR (1) | BR9501921A (en) |
CA (1) | CA2155202A1 (en) |
DE (1) | DE69420125D1 (en) |
NZ (1) | NZ276707A (en) |
PH (1) | PH31386A (en) |
RU (1) | RU2137765C1 (en) |
WO (1) | WO1995015956A1 (en) |
ZA (1) | ZA949545B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6416733B1 (en) | 1996-10-07 | 2002-07-09 | Bristol-Myers Squibb Pharma Company | Radiopharmaceuticals for imaging infection and inflammation |
WO1998042346A1 (en) * | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating ischemia reperfusion injury |
US6515124B2 (en) | 2000-02-09 | 2003-02-04 | Hoffman-La Roche Inc. | Dehydroamino acids |
AU2002230576A1 (en) | 2000-11-03 | 2002-05-15 | Bristol-Myers Squibb Pharma Company | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation |
US7989454B2 (en) * | 2007-12-17 | 2011-08-02 | Hoffmann-La Roche Inc. | Leukotriene B4 inhibitors |
US8093253B2 (en) * | 2008-03-06 | 2012-01-10 | Hoffmann-La Roche Inc. | Leukotriene B4 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0017332B1 (en) * | 1979-03-20 | 1985-07-31 | FISONS plc | Pharmaceutical heterocyclic compounds, processes for their preparation and compositions containing them |
IE54269B1 (en) * | 1981-12-30 | 1989-08-02 | Ici America Inc | Pharmaceutically active phenylcarboxylic acid derivatives |
US4665203A (en) * | 1983-08-08 | 1987-05-12 | G. D. Searle & Co. | Substituted dihydrobenzopyrans useful as leukotriene D4 inhibitors |
US4952705A (en) * | 1983-08-08 | 1990-08-28 | G. D. Searle & Co. | Substituted dihydrobenzopyrans |
US4686235A (en) * | 1983-10-12 | 1987-08-11 | Merck & Co., Inc. | Substituted cinnamyl-2,3-dihydrobenzofuran and analogs useful as anti-inflammatory agents |
US4683325A (en) * | 1984-01-23 | 1987-07-28 | Merck Frosst Canada, Inc. | Leukotriene antagonists |
US4565882A (en) * | 1984-01-06 | 1986-01-21 | G. D. Searle & Co. | Substituted dihydrobenzopyran-2-carboxylates |
US4546194A (en) * | 1984-05-29 | 1985-10-08 | G. D. Searle & Co. | Substituted chromanon-2-yl alkanols and derivatives thereof |
US4935529A (en) * | 1986-01-31 | 1990-06-19 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Cytoxic substances from the marine cyanophyte hormothamnion enteromorphoides grunow |
ZA873745B (en) * | 1986-06-04 | 1988-10-26 | Daiichi Seiyaku Co | Benzopyran derivatives |
US4889871A (en) * | 1987-05-29 | 1989-12-26 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives |
US5219883A (en) * | 1988-05-20 | 1993-06-15 | G. D. Searle & Co. | 2,2-di-substituted benzopyran leukotriene-D4 antagonists |
US4950684A (en) * | 1988-05-20 | 1990-08-21 | G. D. Searle & Co. | 2,2-di-substituted benzopyran leukotriene-D4 antagonists |
US5273999A (en) * | 1991-09-10 | 1993-12-28 | Hoffmann-La Roche Inc. | Carboxylic acid leukotriene B4 antagonists |
CA2089012A1 (en) * | 1992-02-21 | 1993-08-22 | Josef Heveling | Process for the preparation of 6-hydroxy-2,5,7,8-tetra- alkyl-2-(4-aminophenoxymethyl) chromans |
-
1993
- 1993-12-07 US US08/164,116 patent/US5457124A/en not_active Expired - Fee Related
-
1994
- 1994-11-26 NZ NZ276707A patent/NZ276707A/en unknown
- 1994-11-26 CN CN94191118A patent/CN1117290A/en active Pending
- 1994-11-26 EP EP95902089A patent/EP0682662B1/en not_active Expired - Lifetime
- 1994-11-26 AT AT95902089T patent/ATE183506T1/en not_active IP Right Cessation
- 1994-11-26 DE DE69420125T patent/DE69420125D1/en not_active Expired - Lifetime
- 1994-11-26 WO PCT/EP1994/003918 patent/WO1995015956A1/en active IP Right Grant
- 1994-11-26 CA CA002155202A patent/CA2155202A1/en not_active Abandoned
- 1994-11-26 AU AU11080/95A patent/AU682737B2/en not_active Ceased
- 1994-11-26 RU RU95122819A patent/RU2137765C1/en active
- 1994-11-26 JP JP7515923A patent/JPH08508515A/en active Pending
- 1994-11-30 ZA ZA949545A patent/ZA949545B/en unknown
- 1994-12-05 PH PH49502A patent/PH31386A/en unknown
-
1995
- 1995-05-05 BR BR9501921A patent/BR9501921A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11813256B2 (en) | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | |
US20240226084A9 (en) | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | |
CN1070849C (en) | Enzyme inhibitors | |
EP1100522B1 (en) | Pulmonary delivery of active agents | |
CN1353609B (en) | Amide substituted imidazoquinolines | |
US6589986B2 (en) | Methods of treating anxiety disorders | |
JP2005510535A5 (en) | ||
CN1251091A (en) | New compound | |
JP2562475B2 (en) | Novel compounds, medical compositions, and methods of treating inflammation and pain | |
RU95122819A (en) | BICYCLIC CARBONIC ACIDS, ANTAGONISTS OF LEUKOTRIENE * 004 | |
JPS62212322A (en) | Medicinal composition and therapy | |
EP3095444A1 (en) | A method of treating peripheral inflammatory disease | |
CN102119140B (en) | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | |
RU2738648C2 (en) | Using the compound for treating chronic anxiety or acute anxiety | |
JP3112944B2 (en) | Pharmaceutical compositions useful as analgesics containing (R) -2- (3-benzoylphenyl) propionic acid | |
US9073884B2 (en) | Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them | |
JP2004513067A (en) | Use of 2-phenylenediamine derivatives for the treatment of infectious diseases | |
JPH05503510A (en) | Compositions and methods containing optically pure (S)-atenolol | |
JP2018517779A (en) | Drug delivery and imaging chemical conjugates, formulations and methods of use thereof | |
WO2024017144A1 (en) | Substituted imidazo [1, 2-a] pyridine compounds and the use thereof in the treatment and prevention of fibrosis | |
JPH09506366A (en) | Leukotriene B Diphenyl-2-propenoate and its homologues useful for treating diseases related to (4) | |
WO2002085347A1 (en) | Preventive/remedial agent for inflammatory disease in oral-cavity mucosa and the like | |
EP0804242A1 (en) | The use of dimeticone as a transport and carrier system and/or drug delivery system | |
TH10148EX (en) | Substitutated carboxytetrahydroisocquinoline and their derivatives, which are pharmacologically active. | |
WO2002096403A1 (en) | Composition containing 2-aminophenylacetic acid |